Bremelanotide and libido claims: what the research actually supports

A viral TikTok clip from Bane Syndicate describes bremelanotide as a “brain-based reboot” for intimate life, claiming it resolves low libido, erectile dysfunction, frigidity, and anorgasmia, and that 80% of users see improvement after the first dose. The video contrasts it with PDE5 inhibitors like sildenafil, emphasizing a central mechanism of action and a 24-hour effect window.

What the research neighborhood actually covers

Bremelanotide is a synthetic peptide analog of α-melanocyte-stimulating hormone that acts as a melanocortin receptor agonist, primarily at MC3 and MC4 receptors. In clinical research, it has been investigated for hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA-approved product (Vyleesi) is indicated for acquired, generalized HSDD, not for men or for erectile dysfunction. Studies show modest improvements in desire scores and a statistically significant increase in satisfying sexual events compared to placebo, but the effect sizes are modest and not universal.

Importantly, the 80% first-use success figure cited in the clip does not appear in peer-reviewed literature. Published trials report responder rates around 30–40% for the primary endpoints, and many participants do not achieve clinically meaningful benefit. The claim of “clinical confirmation” for 80% is not supported by the available evidence.

Limits of the evidence

Research on bremelanotide is limited by short trial durations (typically 12–24 weeks), exclusion of men in pivotal trials, and a lack of long-term safety data. Common adverse events include nausea (about 40%), flushing, and injection-site reactions. The clip’s assertion that it “reduces anxiety” is not a labeled indication, and the mechanism described—enhancing blood flow to erogenous zones—oversimplifies the pharmacology. Bremelanotide does not directly increase blood flow; it modulates central pathways that may influence sexual arousal and desire.

Additionally, the clip claims no interaction with food or alcohol, but the label advises avoiding alcohol due to potential increased blood pressure, and the drug is contraindicated in uncontrolled hypertension. The “spontaneous” use claim is misleading because the injection must be administered 45 minutes before sexual activity, and the effect may not persist for 24 hours in all users.

Research-use caveat

For research-use-only (RUO) peptide suppliers, bremelanotide is intended for laboratory investigation, not human use. Any claims about clinical efficacy or safety are outside the scope of RUO products. Researchers should consult primary literature and regulatory documents when designing studies, and avoid extrapolating from social media claims.

Open the full video fact-check page (transcript, takeaways, embedded clip).